U.S. markets close in 4 hours 52 minutes

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.0650-0.1650 (-5.11%)
As of 11:08AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.2300
Bid3.0800 x 1100
Ask3.0900 x 2900
Day's Range3.0500 - 3.2050
52 Week Range2.4900 - 5.4400
Avg. Volume4,504,246
Market Cap788.741M
Beta (5Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-0.3750
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MNKD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MannKind Corporation
    Analyst Report: Lilly(Eli) & CoEli Lilly, based in Indianapolis, develops and manufactures therapies to treat pain, diabetes, cancer, and neurodegenerative diseases. The shares are a component of the S&P 500.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • InvestorPlace

    7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up

    Penny sleeper stocks can offer tremendous risks to investors. However, much like any other speculative investment category, it’s possible that traders can still generate incredible, perhaps life changing profits. Let’s start with the pros of penny sleeper stocks. Psychologically, these stocks offer an enticing profile because they feature a “cheap” price. It’s hard to quantify much like the tingles you feel from watching a hypnotic ASMR video is difficult to quantify. However, investors tend to

  • Simply Wall St.

    When Can We Expect A Profit From MannKind Corporation (NASDAQ:MNKD)?

    With the business potentially at an important milestone, we thought we'd take a closer look at MannKind Corporation's...

  • GlobeNewswire

    MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022. The Company’s webcast presentation will